Thomas Longerich

19.0k total citations · 3 hit papers
205 papers, 7.4k citations indexed

About

Thomas Longerich is a scholar working on Molecular Biology, Hepatology and Oncology. According to data from OpenAlex, Thomas Longerich has authored 205 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Molecular Biology, 63 papers in Hepatology and 52 papers in Oncology. Recurrent topics in Thomas Longerich's work include Liver Disease Diagnosis and Treatment (44 papers), Hepatocellular Carcinoma Treatment and Prognosis (32 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (21 papers). Thomas Longerich is often cited by papers focused on Liver Disease Diagnosis and Treatment (44 papers), Hepatocellular Carcinoma Treatment and Prognosis (32 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (21 papers). Thomas Longerich collaborates with scholars based in Germany, United States and Netherlands. Thomas Longerich's co-authors include Peter Schirmacher, Kai Breuhahn, Lars Zender, Christian Trautwein, Robert Geffers, Frank Tacke, Volker Ehemann, Tetyana Yevsa, Tom Luedde and Tim F. Greten and has published in prestigious journals such as Cell, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Thomas Longerich

202 papers receiving 7.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression

2016 447 citations Sabrina Klotz, Thomas Longerich et al. profile →
Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis

2017 421 citations Tom Luedde, Thomas Longerich et al. profile →
Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade

2023 176 citations Thomas Longerich et al. Gut profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Longerich Germany	45	3.3k	1.9k	1.8k	1.7k	1.4k	205	7.4k
Kwan Man Hong Kong	53	3.2k 1.0×	1.8k 0.9×	1.6k 0.9×	2.1k 1.2×	1.5k 1.1×	176	7.7k
Toshiharu Sakurai Japan	45	2.8k 0.8×	2.0k 1.1×	1.5k 0.8×	2.1k 1.2×	2.4k 1.8×	191	8.1k
Taro Yamashita Japan	46	4.5k 1.4×	1.8k 0.9×	2.9k 1.5×	2.7k 1.6×	2.8k 2.1×	240	9.4k
Shinji Tanaka Japan	47	3.9k 1.2×	1.1k 0.6×	1.8k 1.0×	1.1k 0.6×	2.3k 1.7×	273	7.5k
Nathalie Wong Hong Kong	46	4.6k 1.4×	1.2k 0.6×	3.0k 1.6×	843 0.5×	1.6k 1.1×	120	7.4k
Matthias Evert Germany	43	3.0k 0.9×	1.0k 0.6×	1.5k 0.8×	805 0.5×	1.3k 1.0×	191	6.5k
Takahiro Kodama Japan	39	2.4k 0.7×	1.3k 0.7×	895 0.5×	884 0.5×	824 0.6×	176	5.8k
Stefan Kubicka Germany	45	2.4k 0.7×	1.3k 0.7×	746 0.4×	1.9k 1.1×	2.4k 1.8×	159	6.4k
Steven Dooley Germany	53	4.5k 1.4×	3.0k 1.6×	1.2k 0.6×	3.7k 2.1×	1.7k 1.2×	237	10.2k
Lopa Mishra United States	49	3.8k 1.2×	798 0.4×	1.5k 0.8×	1.1k 0.6×	2.7k 2.0×	169	7.8k

Countries citing papers authored by Thomas Longerich

Since Specialization

Citations

This map shows the geographic impact of Thomas Longerich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Longerich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Longerich more than expected).

Fields of papers citing papers by Thomas Longerich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Longerich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Longerich. The network helps show where Thomas Longerich may publish in the future.

Co-authorship network of co-authors of Thomas Longerich

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Longerich. A scholar is included among the top collaborators of Thomas Longerich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Longerich. Thomas Longerich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chang, De‐Hua, Philipp Mayer, Jakob Liermann, et al.. (2025). Longitudinal CE-MRI-based Siamese network with machine learning to predict tumor response in HCC after DEB-TACE. Cancer Imaging. 25(1). 104–104.

Weykamp, Fabian, Katharina Seidensaal, Christoph Springfeld, et al.. (2025). Stereotactic body radiotherapy with carbon ions as local ablative treatment in patients with primary liver cancer. Radiation Oncology. 20(1). 23–23. 1 indexed citations

Salié, Henrike, Antonio D’Alessio, Jürgen Beck, et al.. (2024). Spatial single-cell profiling and neighbourhood analysis reveal the determinants of immune architecture connected to checkpoint inhibitor therapy outcome in hepatocellular carcinoma. Gut. 74(3). 451–466. 20 indexed citations

Schwab, Constantin, Uta Merle, Peter Schirmacher, & Thomas Longerich. (2023). Lethality of SARS‐CoV‐2 infection—a comparative autopsy study focusing on COVID‐19 development and virus variants. Histopathology. 83(2). 242–251. 7 indexed citations

Tóth, Marcell, et al.. (2023). Ashwagandha‐induced acute liver injury: A case report. SHILAP Revista de lepidopterología. 11(3). e7078–e7078. 12 indexed citations

Schira‐Heinen, Jessica, Rossella Pellegrino, Lara R. Heij, et al.. (2023). Uncovering Novel Roles of miR-122 in the Pathophysiology of the Liver: Potential Interaction with NRF1 and E2F4 Signaling. Cancers. 15(16). 4129–4129. 1 indexed citations

Ramouz, Ali, Elias Khajeh, Mohammad Golriz, et al.. (2023). Surgical management of primary liver cancers during the COVID-19 pandemic: overcoming the dilemma with standardization. HPB. 25(8). 907–914. 2 indexed citations

D’Artista, Luana, Iros Barozzi, Amanda J. Craig, et al.. (2023). MYC determines lineage commitment in KRAS-driven primary liver cancer development. Journal of Hepatology. 79(1). 141–149. 18 indexed citations

Nienhüser, Henrik, Julian Musa, Georg Martin Haag, et al.. (2023). Clinical Characteristics and Oncological Outcomes of Surgically Treated Early-Onset Gastric Adenocarcinoma - a Retrospective Cohort Study. Journal of Cancer. 14(9). 1470–1478. 12 indexed citations

10.

Schmidt, Sandra, Joanna Kosacka, M Roderfeld, et al.. (2022). Human Mesenchymal Stromal Cells Resolve Lipid Load in High Fat Diet-Induced Non-Alcoholic Steatohepatitis in Mice by Mitochondria Donation. Cells. 11(11). 1829–1829. 19 indexed citations

11.

Pellegrino, Rossella, Abhishek Thavamani, Diego F. Calvisi, et al.. (2021). Serum Response Factor (SRF) Drives the Transcriptional Upregulation of the MDM4 Oncogene in HCC. Cancers. 13(2). 199–199. 8 indexed citations

12.

Mohs, Antje, Tobias Otto, Kai Markus Schneider, et al.. (2020). Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis. Journal of Hepatology. 74(3). 638–648. 102 indexed citations

13.

Loosen, Sven H., Nadine T. Gaisa, Maximilian Schmeding, et al.. (2020). Prolonged Survival of a Patient with Advanced-Stage Combined Hepatocellular-Cholangiocarcinoma. Case Reports in Gastroenterology. 14(3). 658–667. 3 indexed citations

14.

Kriegsmann, Mark, Christiane Zgorzelski, Rita Casadonte, et al.. (2020). Mass Spectrometry Imaging for Reliable and Fast Classification of Non-Small Cell Lung Cancer Subtypes. Cancers. 12(9). 2704–2704. 19 indexed citations

15.

Lenz, Dominic, Mirjam Stahl, Elias Seidl, et al.. (2020). Rescue of respiratory failure in pulmonary alveolar proteinosis due to pathogenic MARS1 variants. Pediatric Pulmonology. 55(11). 3057–3066. 19 indexed citations

16.

Eduati, Federica, Ramesh Utharala, Dharanija Madhavan, et al.. (2018). A microfluidics platform for combinatorial drug screening on cancer biopsies. Nature Communications. 9(1). 2434–2434. 188 indexed citations

17.

Mohs, Antje, Kim Ohl, Guido Hooiveld, et al.. (2016). Hepatic overexpression of cAMP-responsive element modulator α induces a regulatory T-cell response in a murine model of chronic liver disease. Gut. 66(5). 908–919. 12 indexed citations

18.

Graham, Rondell P., Long Jin, Darlene L. Knutson, et al.. (2015). DNAJB1-PRKACA is specific for fibrolamellar carcinoma. Modern Pathology. 28(6). 822–829. 114 indexed citations

19.

Longerich, Thomas, Carolin Mogler, Sebastian Aulmann, et al.. (2010). Annexin A2 as a differential diagnostic marker of hepatocellular tumors. Pathology - Research and Practice. 207(1). 8–14. 33 indexed citations

20.

Schirmacher, Peter & Thomas Longerich. (2009). Hochdifferenzierte Lebertumoren : Neue Entwicklungen und ihre diagnostische Relevanz (Meet the Expert). Der Pathologe. 30(2). 200–206. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact